Literature DB >> 11103049

Design, implementation, and evaluation at entry of a prospective cohort study of homosexual and bisexual HIV-1-negative men in Belo Horizonte, Brazil: Project Horizonte.

M Carneiro1, C M de Figueiredo Antunes, M Greco, E Oliveira, J Andrade, L Lignani, D B Greco.   

Abstract

BACKGROUND AND OBJECTIVES: Project Horizonte, an open cohort of homosexual and bisexual HIV-1-negative men, is a component of the Minas Gerais AIDS Vaccine Program of the Federal University of Minas Gerais, Belo Horizonte, Brazil. Its objectives included the evaluation of seroincidence of HIV, to ascertain the role of counseling on behavior modification and to assess their willingness to participate in future HIV vaccine trials.
METHODS: Various means of recruitment were used, including pamphlets, notices in community newspapers, radio, and television, at anonymous testing centers, and by word of mouth.
RESULTS: From October 1994 to May 1999, 470 volunteers were enrolled. Their mean age was 26 years and over 70% of them had high school or college education. During the follow-up, they were seen every 6 months, when they received counseling and condoms, and when HIV testing was done. Eighteen seroconversions were observed, and the incidence rates estimates were 1.75 per 100 and 1.99 per 100 person-years, for 36 and 48 months of follow-up, respectively. During the entire period, 139 volunteers were lost to follow-up. Among them, 59 (42.4%) never returned after the initial visit and 51 (36.7) came only once after their initial visit. No losses were observed for those observed during follow-up for more than 3 years. At enrollment, 50% of participants said they would participate in a vaccine trial, and 30% said they might participate.
CONCLUSIONS: The results obtained up to this moment confirm the feasibility of following this type of cohort for an extended period, estimating HIV incidence rate, and evaluating counseling for safe sexual practices in preparation for clinical trials with candidate HIV vaccines in Brazil.

Entities:  

Mesh:

Year:  2000        PMID: 11103049     DOI: 10.1097/00042560-200010010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  HIV vulnerability of men who have sex with men in developing countries: Horizons studies, 2001-2008.

Authors:  Scott Geibel; Waimar Tun; Placide Tapsoba; Scott Kellerman
Journal:  Public Health Rep       Date:  2010 Mar-Apr       Impact factor: 2.792

Review 2.  HIV prevalence among female sex workers, drug users and men who have sex with men in Brazil: a systematic review and meta-analysis.

Authors:  Monica Malta; Monica M F Magnanini; Maeve B Mello; Ana Roberta P Pascom; Yohana Linhares; Francisco I Bastos
Journal:  BMC Public Health       Date:  2010-06-07       Impact factor: 3.295

3.  So different, yet so similar: meta-analysis and policy modeling of willingness to participate in clinical trials among Brazilians and Indians.

Authors:  Guilherme Zammar; Henrique Meister; Jatin Shah; Amruta Phadtare; Luciana Cofiel; Ricardo Pietrobon
Journal:  PLoS One       Date:  2010-12-16       Impact factor: 3.240

4.  Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte, Brazil--1996-2012.

Authors:  Unaí Tupinambás; Helena Duani; Ana Virgínia Cunha Martins; Agdemir Waleria Aleixo; Dirceu Bartolomeu Greco
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-06       Impact factor: 2.743

5.  Risk factors associated with HIV infection among male homosexuals and bisexuals followed in an open cohort study: Project Horizonte, Brazil (1994-2010).

Authors:  Ana Paula Silva; Marília Greco; Maria Arlene Fausto; Dirceu B Greco; Mariângela Carneiro
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

6.  Loss to follow-up in a cohort of HIV-negative men who have sex with men: Project Horizonte.

Authors:  Ana Paula Silva; Marília Greco; Maria Arlene Fausto; Mariângela Carneiro
Journal:  Rev Saude Publica       Date:  2017-06-26       Impact factor: 2.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.